Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

The 2022 Tandem Meetings | Are we ready for MRD-guided therapy in multiple myeloma?

Radhika Bansal • 11 Apr 2022
The 2022 Tandem Meetings
Multiple Myeloma

Radhika Bansal, MBBS, Mayo Clinic, Rochester, MN, talks on the use of measurable residual disease (MRD) in multiple myeloma. MRD can be used to predict the risk of relapse and guide risk-adapted monitoring. According to Dr Bansal, it would be useful to combine different technologies with varying sensitivities to assess a patient’s global MRD status. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.

More from Radhika Bansal

2:22
Outpatient management of CAR-T therapy in multiple myeloma and lymphoma
Radhika Bansal • 9 Dec 2023
1:49
Outpatient management of patients with multiple myeloma treated with bispecific antibodies
Radhika Bansal • 9 Dec 2023
2:00
Prognostic tool to identify CAR-T outcomes in patients with aggressive lymphoma
Radhika Bansal • 11 Dec 2022
2:23
Prophylactic dexamethasone use with CAR-T therapy: real-world practice and outcomes
Radhika Bansal • 11 Dec 2022

Related Videos

1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
3:23
Molecular characteristics associated with increased risk of disease progression in SMM
Mark Bustoros • 27 Sep 2023
The content of VJHemOnc is intended for healthcare professionals